Author: Ravi Shankar

RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 before market open on Thursday, November 5th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

To listen by phone, investors may dial 800-715-9871 (646-307-1963 for international callers) and enter access code 2208277. The live webcast will be available through the Certara Earnings Webcast link and the Investor Relations section of the Company’s website at ir.certara.com, where a replay will be archived.

About Certara

Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.

Investor Relations and Media Contact: 

Jeff Warren and Jay Liu
ir@certara.com

Holders choose the price at which they tender; offer provides an optional path to liquidity, and holders who do not tender retain all existing rights

WAYNE, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) — BTCS Inc. (NASDAQ: BTCS) (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, a company focused on decentralized finance and blockchain infrastructure operations, today announced that it has commenced a cash tender offer to purchase shares of its Series V Preferred Stock (the “Series V Shares”) having an aggregate purchase price of up to $500,000, at a price per share of not less than $0.04 nor more than $1.00, net to the seller in cash, without interest and less any applicable withholding taxes (the “Offer”).

The Offer is being conducted through a “modified Dutch auction.” Holders may tender Series V Shares at a price they specify within the range, in increments of $0.01, or elect to tender “at the purchase price.” When the Offer expires, the Company will determine the lowest single price within the range that allows it to purchase Series V Shares having an aggregate purchase price of up to $500,000 (or all shares tendered, if fewer), and will pay that price for every share it purchases, including shares tendered at lower prices. Shares tendered above the purchase price will not be purchased. If the Offer is oversubscribed at the purchase price, shares will be purchased on a pro rata basis.

The Company has set a wide price range because there is no trading market for the Series V Shares and therefore no market price to anchor a range to; the purchase price will be determined by the prices at which holders choose to tender.

The Offer will expire at 5:00 p.m., New York City time, on December 15, 2026, unless extended or earlier terminated by the Company. Tendered Series V Shares may be withdrawn at any time before the expiration of the Offer. The Offer is not conditioned on any minimum number of shares being tendered or on financing. The Offer is subject to the conditions described in the Offer to Purchase. The Company’s directors and executive officers have advised the Company that they will not tender any Series V Shares in the Offer.

“The Series V was distributed to every BTCS shareholder in 2023, and since then U.S. holders have had no practical way to sell it,” said Charles Allen, Chief Executive Officer of BTCS. “This Offer gives each holder a choice, and lets holders rather than the Company set the price. Holders who would like cash now can tender at the price they choose. Holders who prefer to keep their Series V can simply do nothing and keep everything they have today.”

About the Series V Preferred Stock

The Series V Shares were distributed on June 2, 2023 to holders of BTCS common stock on a one-for-one basis. The Series V Shares are non-voting, are not listed on any securities exchange and have no established trading market. At the Company’s 2024 annual meeting, shareholders approved an amendment authorizing the Board of Directors, in its discretion, to convert each Series V Share into one share of common stock. The Board has not exercised that authority, and under the terms of the Company’s July 2025 convertible note financing and the extension of that restriction agreed in connection with the noteholders’ consent to the Offer, the Company may not amend the Series V Shares to provide for conversion while any of the notes issued in its May 2025 and July 2025 convertible note financings remain outstanding. The July 2025 notes are scheduled to mature on July 21, 2027. The Company has stated that it may explore options to create liquidity for the Series V Shares and may ultimately seek to convert the Series V Shares into common stock when the restriction expires. The Board has made no decision to convert the Series V Shares, and no holder should tender based on any assumption about whether or when a conversion will occur.

How to Tender

Holders who hold Series V Shares through a broker, bank or other nominee should contact their nominee, which will present the Offer as a voluntary corporate action and tender on the holder’s behalf through The Depository Trust Company at the price the holder specifies. Nominees may set deadlines earlier than the expiration of the Offer. Holders whose shares are registered directly with the Company’s transfer agent, Equity Stock Transfer, LLC, should complete the Letter of Transmittal, including the price at which they are tendering, and return it to the depositary as described in the Offer to Purchase. The Offer is being made solely by the Offer to Purchase and related Letter of Transmittal dated October 26, 2026.

InvestorCom LLC is serving as information agent for the Offer, and Equity Stock Transfer, LLC is serving as depositary. Questions and requests for copies of the Offer documents may be directed to InvestorCom toll-free at (877) 972-0090 or by email at proxy@investor-com.com. The Offer documents are also available free of charge at www.sec.gov and at www.btcs.com/seriesv-tender. 

No Recommendation

None of the Company, its Board of Directors, the information agent or the depositary makes any recommendation as to whether holders should tender or refrain from tendering Series V Shares, or as to the price at which holders may choose to tender. Holders must make their own decision after reading the Offer to Purchase and consulting their own financial, tax and legal advisors. The maximum price in the range is below the current market price of the Company’s common stock, and the Offer to Purchase describes the reasons for the Offer, its effects and the related risks in detail.

Important Information

This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any Series V Shares. The Offer is being made only pursuant to the Offer to Purchase, the Letter of Transmittal and related materials that the Company has filed with the Securities and Exchange Commission as exhibits to a Tender Offer Statement on Schedule TO. Holders of Series V Shares are urged to read the Schedule TO, the Offer to Purchase, the Letter of Transmittal and the other Offer documents carefully because they contain important information, including the terms and conditions of the Offer. These documents are available free of charge at the SEC’s website at www.sec.gov and from the information agent.

About BTCS Inc.

BTCS Inc. (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and asset accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance (“DeFi”) and traditional finance (“TradFi”) mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking), Builder+ (block building), and Imperium (DeFi deployments), BTCS offers a unique opportunity for blockchain exposure, driven by recurring on-chain revenue generation and an Ethereum-focused strategy. Discover how BTCS offers exposure to Ethereum and its on-chain economy through the public markets at www.btcs.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the timing, completion and effects of the Offer, the purchase price that may result, the sources of funds for the Offer, and whether, when and on what terms the Company may create liquidity for or convert the Series V Shares. These statements are based on current expectations and involve risks and uncertainties, including the conditions to the Offer, the number of shares tendered and the prices at which they are tendered, the Company’s financial condition and access to capital, the price of Ether and other digital assets, regulatory developments, and the other risks described in the Company’s filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Actual results may differ materially. The Company undertakes no obligation to update forward-looking statements except as required by law. The safe harbor provisions of the Private Securities Litigation Reform Act of 1995 do not apply to statements made in connection with a tender offer.

Contact

Charles Allen – CEO
X: @Charles_BTCS
Email: ir@btcs.com

Study combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development

Source: Oncotelic Therapeutics, Inc.

AGOURA HILLS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”) today announced the publication of a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (“HCC”), a form of liver cancer. The study used Partitioned Literature Aggregation (“PLA”), Oncotelic’s patented algorithm running on PDAOAI, in combination with subsequent transcriptomic and survival analysis.

Published October 23, 2026, the study illustrates a practical application of PDAOAI: organizing scientific evidence to uncover the unknowns without prompt engineering. PLA examines defined literature groups separately before aggregating the findings.

From literature evidence to a testable biological hypothesis

Separate gene-expression and survival analyses identified a four-gene signature comprising FKBP1A (FKBP prolyl isomerase 1A), EIF4E (eukaryotic translation initiation factor 4E), RRAGC (Ras related GTP binding C) and PPARGC1A (PPARG coactivator 1 alpha). The four-gene signature’s association with survival was independently validated in a Japanese HCC cohort of 203 patients. The findings define patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus.

“Development of everolimus has stalled over the years,” said Saran Saund, Chief Business Officer of Oncotelic. “PLA sorted through large amounts of data to arrive at validated biomarkers for clinical development. Here, PLA defined a new pathway for the treatment of liver cancer with an mTOR inhibitor. The robustness of the analyses gave us the confidence to advance these findings into clinical development.”

The study is available open access in Biomedicines, Volume 14, Issue 11, article 2438: Read the paper. Chang, W.-H. et al. Partitioned Literature Aggregation and Transcriptomic Survival Analysis Identify an Immune-Contextualized Four-Gene mTOR Prognostic Composite in Hepatocellular Carcinoma. Biomedicines 2026, 14, 2438. https://doi.org/10.3390/biomedicines14112438.

Connecting focused investigations with larger discovery programs

Saund presented the approach during his October 22 keynote at the 22nd Drug Discovery Strategic Summit at The Westin San Francisco Airport in Millbrae, California.

The presentation also examined Anthropic’s reported use of parallel AI-agent investigations to identify an overlooked biological system.

A recent OpenAI collaboration with PerturbAI and Scripps Research further illustrates the organizing principle behind Partitioned Literature Aggregation (PLA): divide a complex problem into focused investigations, examine the evidence and combine the findings. By assigning 1,946 AI agents to individual gene perturbations in mouse-brain data, the researchers identified a potential link between DCTN1 dysfunction and cholesterol regulation relevant to Perry syndrome, a neurodegenerative disorder with Parkinson-like symptoms. Oncotelic views this work as an independent example of how partitioned investigation and evidence aggregation can generate testable biological hypotheses.

As previously announced, Oncotelic plans to extend its PDAOAI discovery platform toward a target scale of approximately 100 billion biological vectors for genetic and protein research. The HCC publication provides a concrete example of the literature-based discovery approach underlying that broader ambition.

PLA is patent pending, with an issued patent in Mexico.

BIO REBOOT

Through BIO REBOOT, individuals and teams can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community. Registration is free at https://pdaoai.com/bio-reboot.

Selected projects may be considered for startup funding and Oncotelic support spanning validation, formulation, regulatory planning and clinical development. Funding, platform access and development support are subject to scientific review, available resources and agreed terms.

About PDAOAI

PDAOAI is an AI-powered drug discovery platform developed by Oncotelic Therapeutics, Inc. Its current platform index covers approximately 29 million PubMed abstracts. It runs Oncotelic’s patented PLA algorithm to address research questions in target discovery, drug repurposing and therapeutic development, with evidence traceable to source publications. Fastbot/Membot is the researcher-facing AI interface that provides individual access to PDAOAI for exploring research questions and developing evidence-supported hypotheses. For more information, visit www.pdaoai.com.

About Oncotelic

Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. Alongside its own drug development programs, the Company licenses and co-develops selected candidates through partnerships and joint ventures, including its 45% interest in GMP Bio. Oncotelic also develops the PDAOAI platform to support its work in drug discovery and development.

Additional information is available at www.oncotelic.com.

Oncotelic Cautionary Note on Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “estimate,” “target” and “will” can identify forward-looking statements.

Forward-looking statements in this release include the development, availability, adoption and potential utility of PDAOAI, PLA and Fastbot; the potential value, scope and future development of its intellectual-property portfolio; plans to extend the platform to genetic and protein discovery at a target scale of approximately 100 billion vectors; the potential significance and further validation of the HCC findings; and BIO REBOOT collaborations, potential startup funding, platform access and development support.

Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all.

Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive.

The Company faces known and unknown risks, including the risk factors described in the Company’s 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026 and in the Company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release.

Except as required by law, the Company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.

Contact information
For Oncotelic Therapeutics, Inc.
Investor Relations
ir@oncotelic.com

FREMONT, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, and Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) today announced that Enphase will deploy the world’s first 900 V gallium nitride (GaN) monolithic bidirectional switch (BDS) devices, designed to operate in Enphase solid-state transformer power modules. The devices extend GaN technology to 900 V while retaining the high-frequency switching capabilities that enable compact, efficient power conversion.

Enphase has pioneered the system-level development and demonstration, building on more than 10 years of in-house research into GaN power conversion, with device technology and engineering expertise from Infineon. Enphase is among the first to bring 650 V GaN BDS devices into volume production power electronics, and GaN HEMT technology is already operating in Enphase IQ9™ Microinverters deployed in the field. Extending that work with Infineon beyond 650 V, using Infineon’s CoolGaN™ bidirectional switch portfolio, opens the door further to medium-voltage systems.

The 900 V GaN devices allow Enphase to continue using components rated below 1 kV, expanding the design options towards high-performance power conversion typically governed by silicon carbide (SiC). This supports a single-stage architecture with high-frequency switching, low electromagnetic interference (EMI), and fewer points of failure. Switching at such high frequency shrinks the transformers and other magnetics needed in the power stage, cutting size, weight, and cost.

Higher-voltage switches within that low-voltage envelope change the economics of power conversion. In a solid-state transformer, a medium-voltage input can be handled by fewer inverters connected in series while retaining the low switching losses and intrinsic bidirectionality of GaN BDS. Fewer building blocks means lower system-level losses at the same input current, fewer components in the power path, and a lower total switch count. On the DC side, higher-voltage unidirectional switch (UDS) devices allow power to be generated at a unipolar 800 volts rather than split +/-400 V buses, and support future 1,500 VDC bus architectures through split +/-750 V generation with fewer switches and lower bridge losses.

The technology is particularly relevant to the Enphase IQ^® Solid-State Transformer (IQ SST), the company’s solid-state transformer platform for AI data centers, where power density, efficiency, and uptime drive the economics of every megawatt deployed. The same devices are expected to benefit commercial solar inverters by enabling three-phase, line-to-line designs for 480 V applications in the United States and 400 V applications elsewhere, again with fewer switches, lower losses, and lower cost.

“Enphase asks more of our technology than almost anyone, and medium-voltage solid-state transformers are exactly where high-voltage GaN proves its value,” said Johannes Schoiswohl, senior vice president and head of GaN Systems Business Line at Infineon. “Moving past 650 V lets system designers strip cost and loss out of the architecture rather than optimizing around it.”

“GaN is not new to us. It has been running in Enphase IQ9 Microinverters in the field, and that field data is why we trust it in a megawatt-class system,” said Hans van Antwerpen, senior vice president and chief technology officer at Enphase Energy. “Moving to 900 V gives us more voltage headroom without giving up high-frequency switching, and it allows us to stay with components rated below 1 kV while reducing the number of converters in the system. Fewer parts in the power path means higher efficiency and fewer things that can fail.”

The 900 V GaN BDS devices have been successfully tested and are now being integrated into IQ SST development builds, with production qualification expected to follow. Learn more about the use of GaN in Enphase products in its white paper.

About Enphase Energy, Inc.

Enphase Energy is a global energy technology company advancing intelligent power systems for homes, businesses, and next-generation AI data centers. The company designs semiconductor-based energy technologies spanning solar, batteries, EV charging, energy management, and virtual power plants, and is developing solid-state transformer technology to address the rapidly growing power demands of AI data centers. Based in Fremont, California, Enphase is the world’s leading supplier of microinverter-based solar and battery systems. The company revolutionized the solar industry with its microinverter technology and has shipped approximately 89.4 million microinverters, with approximately 5.3 million Enphase-based systems deployed in more than 165 countries. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected capabilities and performance of Enphase Energy’s IQ SST, including safety, quality, reliability, efficiency, scalability, and power conversion capabilities; the expected capabilities, performance, and benefits of 900 V GaN BDS devices, including operation in IQ SST power modules; the expected benefits of extending GaN technology beyond 650 V, including reduced losses, lower system cost, higher power density, fewer components, lower switch counts, and improved system efficiency; the expected benefits of Enphase’s collaboration with Infineon Technologies AG; the integration, qualification, and deployment of 900 V GaN BDS devices in IQ SST and other Enphase products; the expected benefits of such devices for AI data center infrastructure, commercial solar inverters, and other power conversion applications; the anticipated use of 900 V GaN BDS devices in future power architectures, including medium-voltage systems and higher-voltage DC bus configurations; and the availability and timing of future product development and production qualification activities. These forward-looking statements are based on Enphase Energy’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, technological development and validation risks; market demand for AI data center infrastructure, commercial solar products, and related power conversion solutions; competitive developments; the ability to achieve anticipated performance, reliability, efficiency, scalability, and cost objectives; manufacturing and supply chain availability and costs; the successful integration, testing, qualification, and commercialization of new semiconductor technologies; and changes in regulatory or compliance requirements. Such risks and uncertainties are more fully described in Enphase Energy’s filings with the Securities and Exchange Commission, including in the sections entitled “Risk Factors” and elsewhere in Enphase Energy’s most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Enphase Energy files from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

Contact:

Enphase Energy
press@enphaseenergy.com

Company to pursue NASDAQ uplisting while maintaining its focus on commercial execution, advancing key growth initiatives, and creating long-term shareholder value

ST. LOUIS, Oct. 26, 2026 (GLOBE NEWSWIRE) — Verde Resources, Inc. (OTCQB: VRDR) (“Verde” or the “Company”), an emerging leader in sustainable infrastructure technologies, today announced that it has filed with the U.S. Securities and Exchange Commission (the “SEC”) a request for withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-292386), initially filed with the SEC on December 23, 2025 and last amended on August 5, 2026 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.

The Registration Statement has not been declared effective, and no securities of the Company were sold in connection with the offering contemplated by the Registration Statement.

The Company emphasizes that this decision does not alter its commitment to uplisting to the Nasdaq Stock Market (“Nasdaq”). The Company remains focused on advancing this objective while continuing to execute its commercial strategy, pursue key growth initiatives, and create long-term shareholder value.

Verde remains firmly committed to its Nasdaq uplisting objective, subject to satisfying all applicable listing requirements and obtaining the necessary approvals. The Company looks forward to providing shareholders with further updates as meaningful milestones are achieved.

About Verde Resources Inc.

Verde Resources Inc. (OTCQB: VRDR) is an emerging leader in environmentally sustainable infrastructure products and technologies, specializing in innovative and cost-effective solutions designed to help the industry seamlessly #TransitionToZero®.

Through its engineered biochar, sustainable road-material technologies and Net Zero Blueprint, Verde is developing solutions designed to reduce greenhouse gas emissions, sequester carbon dioxide, expand the use of recycled and locally available materials, and transform conventional infrastructure into a platform for measurable carbon storage.

For more information, please visit www.verderesources.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of Verde’s management made in connection with the matters addressed by this press release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Verde’s expectations, projections, and potential future developments. Statements attributed to Verde reflects its views as of the date hereof and are not intended as guarantees of future performance. All forward-looking statements are subject to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Forward-looking statements involve significant known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially and adversely from those expressed or implied. In some cases, forward-looking statements can be identified by words such as “may,” “will,” “expect,” “plan,” “believe,” “estimate,” “anticipate,” “project,” “seek,” “propose,” “intend,” “aim,” “goal,” “potential,” “explore” or derivations of such words or similar expressions regarding the future, although forward-looking statements may be denoted by other terms. In this press release, forward-looking statements include those related to Verde’s product potential, commercialization strategy, commercial collaborations, capital markets strategies, growth initiatives, and creation of shareholder value. These and other statements are based on current expectations and speak only as of the date of this release.

A non-exclusive list of risks and uncertainties that could cause the forward-looking statements herein to differ from future results includes, without limitation: (i) the risk that Verde will not be successful in its attempt to meet the initial listing qualifications or receive approval to uplist to Nasdaq or another national securities exchange, (ii) the risk that Verde’s capital markets strategies will be less successful than currently contemplated, if at all, and (iii) risks related to Verde’s executing on its commercial strategy, advancing its growth initiatives, and creating long-term shareholder value as currently contemplated, to a lesser degree, or at all. Other important factors that could cause actual results to differ materially from those in the forward-looking statements include those contained in the Verde’s filings with the SEC, which can be accessed here.

Accordingly, readers are cautioned not to place undue reliance on the forward-looking statements contained herein. Except as required by applicable law, Verde does not plan to publicly update or revise any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances, or otherwise.

For Media and Investors:

Verde Resources, Inc.
info@verderesources.com

C2C Advisors, LLC 
+1-516-295-2111

TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) will release financial results for the quarter ended September 30, 2026 on Wednesday, November 11, 2026 after market close. The Company will host a live conference call and webcast on Thursday, November 12, 2026 to discuss results with analysts and investors.

Conference Call Details:
Date: Thursday, November 12, 2026
Time: 1:00 p.m. Eastern Time
Webinar Link: https://us02web.zoom.us/j/85394773035?pwd=mFDxiib55443W9wdMb8evhhbferWkc.1
Webinar ID: 853 9477 3035
Passcode: 1234

To join by telephone (higher quality audio):
Canada: +1 780 666 0144 | +1 204 272 7920 | +1 438 809 7799 | +1 587 328 1099 | +1 647 374 4685 | +1 647 558 0588 | +1 778 907 2071
International numbers: https://us02web.zoom.us/u/kbE03DvhIf

Speakers will receive a separate webinar link.

The playback of the conference call will also be available on www.timbercreekfinancial.com following the call.

About Timbercreek Financial

Timbercreek Financial is a leading non-bank, commercial real estate lender providing shorter-duration, structured financing solutions to commercial real estate investors. Our sophisticated, service-oriented approach allows us to meet the needs of borrowers, including faster execution and more flexible terms that are not typically provided by Canadian financial institutions. By employing thorough underwriting, active management and strong governance, we are able to meet these needs while targeting strong risk-adjusted returns for investors.

For further information, please contact:

Katrina Gorzheltson
Vice President, Investor Relations
kgorzheltson@timbercreek.com
www.timbercreekfinancial.com

RESTON, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) — Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media, today announced that it plans to hold a conference call to discuss its financial results for the third quarter ended September 30, 2026 on Tuesday November 3rd at 5:00 p.m. ET.

Interested parties may access the conference call via live webcast at https://edge.media-server.com/mmc/p/gf3tn5xm or participate via telephone by registering in advance at https://register-conf.media-server.com/register/BIf2473d7e7d144aceb23cb6312d24d732.

Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call.

Following the conference call, a replay will be available via webcast at https://ir.comscore.com/events-presentations.

About Comscore 
Comscore is a trusted global partner for planning, activating, and evaluating media across platforms. Its unmatched data footprint brings together Connected TV (CTV), digital, national and local linear TV intelligence with advanced audience insights to help media buyers and sellers understand how audiences engage across screens and make business decisions with confidence. Comscore is a preeminent provider of independent, comprehensive cross-platform measurement and decisioning solutions designed to improve outcomes at scale.

Investors 
Jackie Marcus or Nick Nelson
Alpha IR Group
(617) 466-9257
investor@comscore.com

Media 
Marie Scoutas
Comscore, Inc.
(917) 213-2032
press@comscore.com

Geneva, Switzerland / New York, United States , Oct. 26, 2026 (GLOBE NEWSWIRE) —

Binding Letter of Intent establishes the initial space and ground infrastructure for QSOC in a transaction estimated to be worth $15 million over the next 18 months, building on recent $10 million PIPE made in WISeSat.Space

 SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”), a developer of semiconductor, Public Key Infrastructure (“PKI”) and post-quantum security technologies, together with its sister company, WISeSat.Space Holdings Corp. (NASDAQ: SAIQ) (“WISeSat.Space”), today announced the signing of a binding letter of intent contemplating SEALSQ’s acquisition of satellite capacity associated with twelve (12) WISeSat.Space satellites, together with access to related mission control, ground segment, and operational support services. The proposed transaction, involving consideration of approximately $15 million is intended to support space-to-device communications and secured transactions for the development of the Quantum Spatial Orbital Cloud (“QSOC”).

The letter of intent represents a milestone in the companies’ strategy to combine secure semiconductors, trusted digital identity and satellite connectivity into sovereign orbital infrastructure.

For SEALSQ, the letter of intent provides the initial infrastructure needed to extend its semiconductor security, digital identity and cryptographic-key management technologies into space-enabled services. SEALSQ intends to develop and commercialize QSOC’s security-services layer, creating a potential source of recurring subscription revenue from government and enterprise customers.

First 12 Satellites and Ground Station to Establish Initial QSOC Infrastructure
The letter of intent covers capacity associated with an initial fleet of 12 satellites, together with mission control, ground segment and operational support services, providing the orbital and terrestrial infrastructure needed to support QSOC’s development.

The ground station is intended to connect the satellite network with terrestrial systems, supporting communications, secure data exchange and integration with SEALSQ’s planned security services. Together, the satellites and ground station would support the integrating semiconductor security, digital identity and cryptographic-key management across the network.

The proposed transaction aligns WISeSat.Space’s infrastructure development with SEALSQ’s strategy to extend its security technologies into space-enabled services.

Developing a Sovereign Orbital Trust Platform
QSOC is intended to combine WISeSat.Space’s satellite infrastructure with SEALSQ’s semiconductor security, PKI and identity technologies. Planned services include:

• Post-quantum-secured satellite communications.
• Trusted identity and authentication for connected devices.
• Secure cryptographic-key provisioning and lifecycle management.
• Access to quantum-generated randomness.
• Secure data exchange between orbital and terrestrial systems.

Under the proposed operating model, WISeSat.Space would be responsible for the supply and launch of the satellites, for providing access to the initial constellation, and for operating the ground station, mission control and associated infrastructure, while SEALSQ would develop and commercialize the security-services layer. The objective is to offer subscription-based services to governments, financial institutions, defense organizations and critical-infrastructure operators.

Bringing Semiconductor Trust into Space
Carlos Moreira, Chairman and CEO of SEALSQ and WISeSat.Space, commented: “This letter of intent is a concrete step towards moving QSOC from vision into infrastructure. The initial 12 satellites, together with mission control, ground infrastructure and operational support, are intended to provide the foundation on which QSOC’s services can be developed.

“Our goal is to extend trust from the semiconductor to the satellite, through the ground station and ultimately to the organizations and devices using the network. Sovereignty requires control over identity, cryptographic keys and the systems that authorize access to data. Through QSOC, we aim to bring these capabilities together across terrestrial and orbital infrastructure, supported by rigorous technical validation.”

John O’Hara, CFO of SEALSQ, commented: “This letter of intent is aimed at extending SEALSQ’s semiconductor security, digital identity and cryptographic-key management technologies into space-enabled services. By securing access to the initial satellite and ground and operational infrastructure for QSOC, we are laying the foundation for a subscription-based security offering that could complement our semiconductor business and create a new source of recurring revenue. Our focus is on disciplined capital deployment, aligning further investment with technical validation and customer demand to build long-term value for SEALSQ shareholders.”

Commercial Development and Deployment Roadmap
The initial 12-satellite constellation and ground-station aims to establish a defined commercial foundation for QSOC. The companies intend to progressively integrate and validate the technologies required to deliver their planned services.

Deployment of individual capabilities and commencement of customer services will depend on technical qualification, infrastructure readiness, regulatory authorizations and customer requirements.

The broader QSOC roadmap envisages progressive deployment of up to 100 satellites through 2033. Expansion remains subject to financing, technical validation, regulatory approvals, launch availability and commercial agreements.

The collaboration creates a potential route for SEALSQ to extend its semiconductor and trusted-identity technologies into space-enabled services, while supporting WISeSat.Space’s development of secure communications infrastructure.

About WISeSat.Space
WISeSat.Space Holdings Corp. (Nasdaq: SAIQ) is a space technology company focused on secure satellite communications and related space infrastructure. Its approach combines satellite infrastructure with cybersecurity and digital identity technologies to support trusted communications between connected devices and ground-based systems. WISeSat.Space intends to provide satellite capacity and related space and ground infrastructure that may support SEALSQ’s planned QSOC roadmap. Visit wisesat.space.

About SEALSQ:
SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.

SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.

For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.

Forward-Looking Statements
This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the closing of the definitive agreements; the proposed transaction’s ability to further SEALSQ’s strategic intention to extend its semiconductor security, digital identity and cryptographic-key management technologies into space-enabled services; SEALSQ’s ability to develop and commercialize QSOC’s security-services layer; SEALSQ’s ability to create a source of recurring subscription revenue from the QSOC; SEALSQ’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ’s filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.

SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SEALSQ Corp. Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@sealsq.com

SEALSQ Investor Relations (US) The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 Lena.cati@theequitygroup.com

SOL treasury reaches 2,595,612 as Solana enters a new era of near-instant transaction finality

CHAD annual dividend rate to increase to 14%, effective November 2, 2026

BOCA RATON, FL, Oct. 26, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that its total holdings of SOL and SOL equivalents increased by 5,346 SOL since its last update, bringing its treasury to approximately 2,595,612 SOL, up from 2,590,266 SOL.

The update comes as Solana’s Alpenglow consensus upgrade went live on mainnet on October 21, marking a major milestone in the network’s evolution.

A Seminal Moment for Solana and Crypto
Alpenglow targets transaction finality of approximately 150 milliseconds, compared with roughly 12.8 seconds under Solana’s previous consensus protocol, a reduction of approximately 99% in the time required for transactions to become final.

The Company believes this advancement strengthens Solana’s potential to serve as infrastructure for global financial markets. Near-instant finality can improve the experience of moving money, trading tokenized assets, and interacting with financial applications onchain.

“Alpenglow is a seminal moment for Solana and for crypto more broadly,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “When transactions become final in a fraction of a second, the possibilities for payments and financial markets expand significantly. We believe Solana is building the foundation for the next generation of finance, and we continue to accumulate and compound SOL to give our shareholders exposure to that opportunity.”

CHAD Annual Dividend Rate Increasing to 14%, Effective November 2, 2026
As previously announced, the annual dividend rate on the Company’s Variable Rate Series C Perpetual Preferred Stock (“CHAD”) will increase from 13.00% to 14.00%, effective November 2, 2026.

The new rate represents annual dividends of $1.40 per share, based on CHAD’s $10.00 stated amount. The current 13.00% annual rate remains in effect until the increase takes effect. Dividends are cumulative and payable each business day when declared.

Through its SOL treasury strategy and CHAD, the Company offers investors distinct ways to participate in its balance sheet: common equity exposure to its strategy of accumulating and compounding SOL, and preferred equity focused on dividend income.

Learn more about CHAD at www.defidevcorp.com/chad.

For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to our blog.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding SOL per share growth; future SOL holdings; anticipated changes in borrowings and liquidity; future SOL accumulation and per-share accretion; future adoption of Solana, tokenized assets and stablecoins; capital raising and deployment; the anticipated issuance price of shares under the CHAD ATM program; future CHAD dividend rates and the declaration and payment of CHAD dividends; the intended use of proceeds; and the Company’s ability to expand its SOL treasury and increase revenue. These statements can be identified by words such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated losses that the Company may incur as a result of a decrease in the market price of SOL; (ii) a failure of demand for SOL, or activity on the Solana network, to continue to develop and grow as we anticipate or at all; (iii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iv) the effect of and uncertainties related to the ongoing volatility in interest rates; (v) our ability to achieve and maintain profitability in the future; (vi) the impact on our business of the regulatory environment and complexities of complying with such environment, including changes in securities laws or other laws or regulations; (vii) changes in the accounting treatment relating to the Company’s SOL holdings; (viii) our ability to respond to general economic conditions; (ix) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (x) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth; (xi) risks relating to CHAD, including that the dividend rate may be adjusted, that dividends are payable only when declared, that CHAD may trade below its stated amount, that the trading price of CHAD may be volatile, that the Company may be unable to sell CHAD under the CHAD ATM at or above its stated amount, and that staking and validator rewards may be insufficient to support dividend payments; and (xii) other risks and uncertainties more fully described in the sections captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, the prospectus supplement for the CHAD ATM and other reports we file with the SEC.

As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this press release are made as of its date, and the Company undertakes no duty to update such information except as required under applicable law.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Offers and sales of CHAD under the CHAD ATM are made only by means of the prospectus supplement and accompanying prospectus forming part of the Company’s effective shelf registration statement on Form S-3 filed with the SEC.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon^® PTH (palopegteriparatide) for up to 5 years in the Company’s Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D., Professor of Medicine at Albany Medical College, during Kidney Week 2026, the annual meeting of the American Society of Nephrology.

“These groundbreaking improvements in renal function underscore the unique ability of TransCon PTH to replicate the systemic and balanced actions of endogenous PTH across multiple target organ systems,” said Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma. “We are pleased to showcase these benefits of TransCon PTH showing simultaneous improvements across key measures that include maintained normal serum calcium, decreased urine calcium, and sustained increases in eGFR, while enabling independence from conventional therapy.”

Historically, management of hypoparathyroidism with conventional therapy consisting of active vitamin D and calcium with the aim of raising serum calcium to the lower half or just below the reference range to alleviate symptoms of hypocalcemia and avoid hypercalciuria, but did not address the missing parathyroid hormone (PTH).ⁱ Today, in contrast, it is possible to provide or restore the full range of effects of PTH that are missing in hypoparathyroidism with TransCon PTH, which provides active PTH within the physiological range for 24 hours/day. The active PTH released from TransCon PTH includes the amino acid sequence identical to the region of endogenous PTH required for receptor activation and enables simultaneous improvements across multiple key clinical and quality-of-life measures.^ii,iii

Data Highlights

• Increases in mean estimated glomerular filtration rate (eGFR) from baseline were statistically significant across patients from Week 26 of treatment through trial completion (p< 0.0001).
  • Mean improvement in eGFR for all patients from baseline to Week 26 was 7.2 mL/min/1.73 m² and to Week 52 was 9.6 mL/min/1.73 m².
  • By Week 52, clinically meaningful improvements in eGFR (≥ 5 mL/min/1.73 m²) ^iv,v were observed in 68.9% of patients, and 49.6% of patients achieved an increase in eGFR of >10 mL/min /1.73 m²; eGFR remained stable through the end of the trials.
  • From Week 52 to Week 266, the mean eGFR slope was 0.28 mL/min/1.73 m²/year, indicating clinically meaningful early improvements in eGFR sustained through up to 5 years, in contrast to the expected typical age-related decline in eGFR in adults.^vi    
  • Patients with baseline eGFR values < 60 mL/min/1.73 m² had a numerically greater increase in mean eGFR than those with a baseline eGFR ≥ 60 mL/min/1.73 m².
• 24-hour urine calcium excretion normalized by Week 26 from mean 396 mg/day at baseline to mean 206 mg/day at Week 26 and further decreased from Week 26 to mean 170 mg/day at Week 52, with improvements sustained through the end of the trials.
• 98% of patients achieved independence from active vitamin D, defined as taking no calcitriol or alfacalcidol, at final trial visit.
• 95% of patients achieved independence from therapeutic doses of calcium, defined as taking <600 mg/day of calcium, at final trial visit.
• Mean serum calcium increased within the normal range to 8.9 mg/dL, with 88% of patients having normal albumin-adjusted serum calcium levels at final trial visit.
• In both trials, TransCon PTH was generally well tolerated, with no new safety signals identified. Most treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1 or 2).

The PaTH Forward and PaTHway trials included a combined total of 141 adults with hypoparathyroidism. The pooled kidney data analysis covers the 139 patients who received at least one dose of TransCon PTH. Of these, 129 completed the final trial visit. The PaTH Forward and PaTHway trials comprised randomized, double-blind, placebo-controlled periods through Weeks 4 and 26 and open-label extension periods through Weeks 266 and 182, respectively. An eGFR ≥30 mL/min/1.73 m² was required for trial eligibility. Mean (SD) baseline eGFR for the pooled analysis was 69 (17) mL/min/1.73 m². The pooled data were analyzed post-hoc and included evaluation of the impact of TransCon PTH on renal function, as assessed by, change from baseline in eGFR and proportion of patients with an increase in eGFR ≥5 mL/min/1.73 m², as well as 24-hour urinary calcium.

About TransCon PTH
TransCon PTH is a prodrug of PTH (1-34), administered once daily, designed to provide active PTH within the physiological range for 24 hours/day, approved as YORVIPATH^® in the United States, European Union, European Economic Area, and other jurisdictions as a treatment for adults with hypoparathyroidism.

About Hypoparathyroidism
Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune, idiopathic, and genetic causes, including ADH1.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) TransCon PTH (palopegteriparatide) data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials, (ii) TransCon PTH’s ability to replicate the systemic and balanced actions of endogenous PTH across multiple target organ systems and to provide or restore the full range of effects of PTH that are missing in hypoparathyroidism, (iii) TransCon PTH’s differentiated profile, including its potential to show simultaneous improvements across key measures while enabling independence from conventional therapy, (iv) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (v) Ascendis’ use of TransCon to develop new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third-party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on-market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom-to-operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YORVIPATH^® are trademarks owned by the Ascendis Pharma group. © October 2026 Ascendis Pharma A/S.

Investor Contact:	Media Contact:
Chad Fugere	Melinda Baker
Ascendis Pharma	Ascendis Pharma
+1 (650) 519-7494	+1 (650) 709-8875

^{__________________________________
i} Khan AA, Bilezikian JP, Brandi ML, et al. J Bone Miner Res. 2022; 37(12):2568-2585.
ⁱⁱ Holten-Andersen L, Pihl S, Rasmussen CE, et al. J Bone Miner Res. Nov 2019;34(11):2075-2086. doi:10.1002/jbmr.3824.
ⁱⁱⁱ Karpf DB, Pihl S, Mourya S, et al. J Bone Miner Res. Aug 2020;35(8):1430-1440. doi:10.1002/jbmr.4016.
^iv Mayne TJ, et al. Clin Transplant. 2021;35(7):e14326.
^v Ku E, et al. J Am Soc Nephrol. 2016;27(7):2196-204.
^vi Guppy M et al. BMJ Open. 2024;14(11):e089783. doi:10.1136/bmjopen-2024-089783.